Success Metrics

Clinical Success Rate

87.5%

Based on 7 completed trials

Completion Rate

88%(7/8)

Active Trials

0(0%)

Results Posted

71%(5 trials)

Terminated

1(13%)

Phase Distribution

Ph phase_4

13%

Ph phase_1

25%

Ph phase_3

38%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

2(33.3%)

Phase 3Large-scale testing

3(50.0%)

Phase 4Post-market surveillance

1(16.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

7 of 8 finished

Non-Completion Rate

12.5%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(7)

Terminated(1)

Detailed Status

Completed7

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

87.5%

Most Advanced

Phase 4

Trials by Phase

Phase 12 (33.3%)

Phase 33 (50.0%)

Phase 41 (16.7%)

Trials by Status

terminated113%

completed788%

Recent Activity

0 active trials

Showing 5 of 8

completed

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

NCT03951103

completedphase_3

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

NCT02234323

completedphase_4

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

NCT03093480

completedphase_3

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

NCT01454739

completedphase_1

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

NCT01027377

View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials

NCT03951103

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Completed

NCT02234323Phase 3

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Completed

NCT03093480Phase 4

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Completed

NCT01454739Phase 3

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

Completed

NCT01027377Phase 1

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Completed

NCT02502149Phase 3

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale

Completed

NCT02392156

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes